Trial NCT04523571 ; ChiCTR2000034825
Publication Zhu F, 2021
Primary outcome on the report: The primary endpoints for safety evaluation were the incidence of solicited local reactions at the injection site or systemic adverse reactions within 14 days post-vaccination, and adverse events following the full immunization until 28 days after receiving the boost dose.